HIV/AIDS Clinical Trials in Chicago

Showing 301-320 of 553 trials

Epic Allies HIV ART Adherence Intervention

NCT02782130

This is a two-arm, randomized-controlled trial (RCT) that will test the acceptability, impact, and long-term sustainability of the Epic Allies intervention application (app), a theory-based mobile app that utilizes game mechanics and social networking features to improve engagement in care, antiretroviral therapy (ART) uptake, ART adherence, and viral suppression among HIV-positive young men who have sex with men (YMSM) and trans women who have sex with men. Subjects will be randomized to either the intervention branch of the Epic Allies app or the control branch of the app.

HIV

University of North Carolina, Chapel Hill146 participantsStarted Jun 2015

Tampa, Florida, United States • Chicago, Illinois, United States • New Orleans, Louisiana, United States +2 more locations

COMPLETEDPhase 22.2 miles

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis

NCT01772823

Approximately 200 HIV-uninfected young men who have sex with men (YMSM) at high risk of acquiring HIV infection, ages 18-22 years, inclusive, will be recruited across all participating Adolescent Medicine Trials Units (AMTU). The behavioral intervention will be assigned at the level of the site, which include Many Men, Many Voices (3MV) and Personalized Cognitive Counseling (PCC). Subjects will first complete the behavioral intervention offered at their respective site and then be provided with open label emtricitabine (FTC)/tenofovir (TDF) (Truvada®) as PrEP. Behavioral and biomedical data will be collected at baseline and 0, 4, 8, 12, 24, 36 and 48 weeks. Any subjects who become HIV infected during the course of the study will be discontinued from the study agent and followed for an additional 24 weeks after the study visit at which HIV infection is confirmed. Those subjects who meet specific bone or renal criteria at the Week 48 visit or the 24-Week HIV Seropositive visit will be followed for an additional 48 weeks in the Extension Phase to monitor longer-term outcomes of potential concerns.

HIV Infection

University of North Carolina, Chapel Hill200 participantsStarted Nov 2012

Los Angeles, California, United States • Aurora, Colorado, United States • Miami, Florida, United States +9 more locations

Epic Allies HIV ART Adherence Intervention

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis

HIV/AIDS Trials in Other Cities

Testing a Secondary Prevention Intervention for HIV-Positive Black Young Men Who Have Sex With Men

Telephone Support to Improve Adherence to Anti-HIV Medications

Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women

Impact of SBI, a Medical Food, on Nutritional Status in Patients With HIV-associated Enteropathy

A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1

GW873140 In Combination With Combivir In HIV Infected Subjects

A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV

Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r)

Intervention for Newly Diagnosed Youth With HIV

Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects

Can Valacyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals?

PRO 140 for Human Immunodeficiency Virus Infection

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes

A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.

Other Conditions in Chicago